Ultragenyx Pharmaceutical Inc. Stock
The price for the Ultragenyx Pharmaceutical Inc. stock decreased slightly today. Compared to yesterday there is a change of -€0.200 (-0.710%).
With 22 Buy predictions and not a single Sell prediction Ultragenyx Pharmaceutical Inc. is an absolute favorite of our community.
With a target price of 78 € there is potential for a 180.58% increase which would mean more than doubling the current price of 27.8 € for Ultragenyx Pharmaceutical Inc..
So far the community has only identified positive things for Ultragenyx Pharmaceutical Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Ultragenyx Pharmaceutical Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
S********** s********
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Ultragenyx Pharmaceutical Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | -0.710% | -7.895% | 0.719% | -34.579% | -32.367% | -33.333% | -79.259% |
| Ironwood Pharmaceuticals | -4.230% | -9.554% | 7.576% | -14.458% | -32.381% | -75.004% | -70.872% |
| Novocure Ltd | 2.000% | -7.868% | 8.408% | -64.776% | -63.204% | -84.730% | -91.827% |
| Iovance Biotherapeutics Inc. | 1.340% | 9.534% | -0.404% | -70.121% | -69.671% | -65.630% | -94.580% |
Comments
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at Barclays PLC from $81.00 to $50.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at TD Cowen from $86.00 to $75.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at Truist Financial Corporation from $100.00 to $90.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
News
Ultragenyx (RARE) Q2 Revenue Up 13%
Ultragenyx Pharmaceutical (NASDAQ:RARE), a rare disease drug developer, reported its second quarter 2025 earnings on August 5, 2025. Both revenue and earnings per share exceeded Wall Street
